DDInter948 DDInter1910
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Valdecoxib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dextromethorphan
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eptifibatide
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enoxaparin
Valdecoxib {u} may lead to a major life threatening interaction when taken with {v} Iohexol
Valdecoxib may cause a minor interaction that can limit clinical effects when taken with Dextromethorphan
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin
Valdecoxib may lead to a major life threatening interaction when taken with Iohexol